musculoskeletal system disease: A disease involving the musculoskeletal system. [database_cross_reference: MONDO:DesignPattern]
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
261 |
4. Check minimum number of eventsNone |
261 |
5. Include endpointsNone |
261 |
6. Filter based on genotype QC (FinnGen only) |
253 |
Control definitions (FinnGen only)
- Control exclude
- M13_OSTEOCHONDRO
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Osteopathy in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Other disorders of bone
- Osteopathies and chondropathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1723 | 895 | 807 |
| Only index persons | 1430 | 752 | 678 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 67.00 | 67.82 | 66.10 |
| Only index persons | 66.54 | 67.84 | 65.10 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 253 | 133 | 120 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 66.19 | 65.29 | 67.18 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 261
- Matched controls
- 2610
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
WF049
NOMESCO Finland
Radiotherapy of metastasis
51.9
183.7
115
39
C90.0
ICD-10 Finland
Multiple myeloma
85.7
137.4
74
12
M90.7*C90.0
ICD-10 Finland
Pathological fracture in multiple myeloma
+∞
136.9
119
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
50.3
121.2
73
20
N02AA05
ATC
oxycodone; systemic
16.1
118.3
174
289
H02AB02
ATC
dexamethasone; systemic
15.2
112.2
141
187
NF3AA
NOMESCO Finland
Femur X-ray examination
48.5
104.5
63
17
WF004
NOMESCO Finland
Palliative radiotherapy
50.5
103.9
62
16
M05BX04
ATC
denosumab; parenteral
21.8
95.5
79
51
Z51.5
ICD-10 Finland
Palliative care
12.6
77.3
92
108
L03AA02
ATC
filgrastim; parenteral
21.0
77.0
63
39
NE1AA
NOMESCO Finland
Pelvis X-ray examination
12.7
74.5
87
99
A04AA01
ATC
ondansetron; systemic, rectal
12.5
74.4
88
102
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
15.3
71.1
70
61
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
15.6
64.9
62
51
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
13.9
59.5
61
56
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
11.1
56.4
69
82
NFB60
NOMESCO Finland
Demanding prosthetic replacement of hip
220.5
53.1
53
*
M90.7
ICD-10 Finland
Fracture of bone in neoplastic disease
+∞
51.8
48
*
WX212
NOMESCO Finland
Femoral plexus blockade
23.2
50.4
38
19
B03XA02
ATC
darbepoetin alfa; parenteral
20.4
49.9
40
23
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.4
47.9
173
616
153
Kela drug reimbursment
Lenalidomid
105.3
47.8
51
6
L04AX04
ATC
lenalidomide; oral
102.7
46.8
50
6
JN4AD
NOMESCO Finland
Body CT examination
7.6
45.0
78
139
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.8
42.1
82
164
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
71.2
41.9
47
8
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
+∞
41.8
39
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
16.7
39.8
35
24
A03FA01
ATC
metoclopramide; systemic, rectal
5.3
39.1
123
376
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
16.0
39.0
35
25
B01AB10
ATC
tinzaparin; parenteral
6.6
38.0
75
151
WW500
NOMESCO Finland
Blood transfusion
9.9
35.8
45
54
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.4
34.4
50
72
XW000
NOMESCO Finland
Bone marrow biopsy
9.7
34.0
43
52
JN4BD
NOMESCO Finland
Extensive body CT
5.8
33.1
74
166
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
13.9
32.1
31
25
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
9.0
32.0
43
56
ZX112
NOMESCO Finland
Subcutaneous
13.4
31.3
31
26
ZX120
NOMESCO Finland
Intravenous
6.0
31.0
65
137
NFR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of hip or thigh
77.7
30.7
34
5
329
Kela drug reimbursment
Lenalidomide
94.1
30.5
33
*
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
6.7
29.2
52
93
C03CA01
ATC
furosemide; systemic
4.1
28.7
136
543
XX3DW
NOMESCO Finland
Time consuming IT work
5.2
27.8
69
168
B01AB05
ATC
enoxaparin; parenteral
3.9
26.8
137
571
NFJ60
NOMESCO Finland
Internal fixation of fracture of other parts of femur with intramedullary nail
149.9
26.1
27
*
TPH04
NOMESCO Finland
Cathetrisation of vein
4.1
25.5
101
351
M04AA01
ATC
allopurinol; systemic
4.5
24.6
74
209
M90.8*N25.0
ICD-10 Finland
Osteopathy in renal osteodystrophy
+∞
24.3
23
*
ZXD05
NOMESCO Finland
Urgent procedure
3.7
24.1
124
511
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
263.1
24.1
24
*
130
Kela drug reimbursment
Malignant tumour
5.2
24.0
58
137
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
27.8
23.7
32
13
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.7
23.3
49
102
393
Kela drug reimbursment
Pomalidomide
131.6
23.0
24
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
9.4
22.3
28
33
M907, C6488,
ICD-10 Finland
+∞
22.2
21
*
NBJ60
NOMESCO Finland
Internal fixation of fracture of shoulder or upper arm using intramedullary nail, humerus
125.6
21.9
23
*
L04AX06
ATC
pomalidomide; oral
125.6
21.9
23
*
L03AA13
ATC
pegfilgrastim; parenteral
6.6
21.7
38
66
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
37.4
21.6
27
8
A28
ICPC
Limited function/disability NOS
4.0
21.4
78
252
NF1AA
NOMESCO Finland
Hip X-ray examination
5.0
21.3
52
123
J01MA12
ATC
levofloxacin; systemic
3.8
21.3
86
298
A04AA02
ATC
granisetron; systemic, transdermal
5.5
21.3
46
98
L02BA03
ATC
fulvestrant; parenteral
65.7
21.3
24
*
WW300
NOMESCO Finland
Transfer of autologic stem cells
65.7
21.3
24
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
8.5
21.3
29
38
WZC00
NOMESCO Finland
Treatment plan or consultation
3.4
21.2
131
596
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
9.0
20.9
27
33
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
20.5
167
891
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
6.7
20.1
34
57
A06AH03
ATC
naloxegol; oral
27.2
20.0
27
11
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.9
19.9
74
241
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.7
19.7
40
80
ZX080
NOMESCO Finland
Image guided radiotherapy
8.8
19.1
25
31
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
5.8
19.0
38
75
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
16.8
19.0
30
20
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.7
18.7
73
245
A79
ICPC
Malignancy NOS
17.0
18.5
29
19
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
56.8
18.2
21
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.6
18.1
76
267
192
Kela drug reimbursment
Fulvestrant
71.8
18.0
20
*
R4110
NOMESCO Finland
Physiotherapy
3.2
17.9
111
495
1507
Kela drug reimbursment
Pomalidomide
102.1
17.8
19
*
NB6AA
NOMESCO Finland
Humerus X-ray examination
14.0
17.6
30
24
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
53.9
17.2
20
*
WF002
NOMESCO Finland
Radical radiotherapy
5.5
17.2
36
74
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
16.6
17.1
27
18
JN4CD
NOMESCO Finland
Very extensive body CT
6.5
16.9
29
49
TPH07
NOMESCO Finland
Cathetrisation of artery
3.9
16.1
55
167
197
Kela drug reimbursment
Sunitinib
64.1
16.0
18
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.5
15.9
33
67
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
15.7
55
170
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.8
15.6
55
171
X59
ICD-10 Finland
Exposure to unspecified factor
3.3
15.3
74
282
S72.3
ICD-10 Finland
Fracture of shaft of femur
48.1
15.3
18
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.2
15.2
45
123
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
6.5
15.1
26
44
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
+∞
14.7
14
*
M05BA02
ATC
clodronic acid; systemic
38.5
14.6
18
5
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
38.5
14.6
18
5
115
Kela drug reimbursment
Breast cancer
4.0
14.5
46
132
WX402
NOMESCO Finland
General anaesthesia
3.0
14.5
82
341
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
20.6
14.5
21
11
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
20.6
14.5
21
11
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.9
14.4
99
458
ZXE10
NOMESCO Finland
More than one and less than three hours
2.7
14.4
129
685
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
18.9
14.1
21
12
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
56.5
14.0
16
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
36.2
13.7
17
5
1501
Kela drug reimbursment
Palbociclib
36.2
13.7
17
5
A11CC03
ATC
alfacalcidol; systemic
12.5
13.6
24
21
YNB10
NOMESCO Finland
Collection of stem cells for transplant
147.3
13.6
14
*
398
Kela drug reimbursment
Ixazomib
147.3
13.6
14
*
J01MA14
ATC
moxifloxacin; systemic
4.0
13.5
42
119
A02BC02
ATC
pantoprazole; systemic
3.1
13.0
208
1451
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
52.8
13.0
15
*
A06AD11
ATC
lactulose; oral
3.2
12.9
61
227
WZC30
NOMESCO Finland
Teaching
3.1
12.9
68
270
C50.4
ICD-10 Finland
Malignant neoplasm: Upper-outer quadrant of breast
33.9
12.7
16
5
AA1AA
NOMESCO Finland
Head X-ray examination
18.5
12.7
19
11
159
Kela drug reimbursment
Pazopanib
73.5
12.7
14
*
8310/3-C64.9
ICD-O-3
Clear cell adenocarcinoma, NOS, of kidney, NOS
21.4
12.6
18
9
L01XE33
ATC
[U] palbociclib
+∞
12.6
12
*
NEK99
NOMESCO Finland
Other operation on bone of pelvis
+∞
12.6
12
*
1502
Kela drug reimbursment
Cabozantinib
136.3
12.5
13
*
3012
Kela drug reimbursment
Cabozantinib
136.3
12.5
13
*
NF3AD
NOMESCO Finland
Femur CT
136.3
12.5
13
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
5.5
12.5
25
49
WW200
NOMESCO Finland
Immunization
13.3
12.4
21
17
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
39.6
12.3
15
*
N03AX16
ATC
[U] pregabalin
2.8
12.2
83
377
L02BA01
ATC
tamoxifen; oral
5.2
12.2
26
54
L28
ICPC
Limited function/disability (L)
3.0
12.1
65
260
WX2DD
NOMESCO Finland
Low-dose CT of skeleton in whole body
49.1
12.0
14
*
S42.3
ICD-10 Finland
Fracture of shaft of humerus
17.5
11.8
18
11
394
Kela drug reimbursment
Palbociclib
31.7
11.8
15
5
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
10.0
11.8
23
25
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.6
11.6
100
510
L02BG04
ATC
letrozole; oral
4.1
11.6
34
92
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.6
11.5
20
17
1505
Kela drug reimbursment
Ixazomib
125.3
11.5
12
*
L01BC06
ATC
capecitabine; oral
4.9
11.2
26
58
L02BB04
ATC
enzalutamide; oral
29.4
10.8
14
5
WW402
NOMESCO Finland
Leucoferesis
114.4
10.5
11
*
M49.5*C90.0
ICD-10 Finland
Vertebral fracture due to multiple myeloma
114.4
10.5
11
*
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
+∞
10.5
10
*
C90.2
ICD-10 Finland
Extramedullary plasmacytoma
+∞
10.5
10
*
B01AB04
ATC
dalteparin; parenteral
4.9
10.5
24
53
S72.2
ICD-10 Finland
Subtrochanteric fracture
34.0
10.4
13
*
N18.0
ICD-10 Finland
End-stage renal disease
19.8
10.4
15
8
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
13.9
10.3
17
13
R50.9
ICD-10 Finland
Fever, unspecified
2.9
10.2
57
231
TK800
NOMESCO Finland
Hemodialysis
12.0
10.2
18
16
L02AE02
ATC
leuprorelin; implant, parenteral
5.1
10.2
22
46
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
3.9
10.1
32
91
163
Kela drug reimbursment
Abiraterone and enzalutamide
27.2
9.9
13
5
WX006
NOMESCO Finland
Intravenous sedation or analgesia without general anesthesia
4.1
9.8
28
74
HAC20
NOMESCO Finland
Total mastectomy
4.8
9.5
22
49
L01XE04
ATC
[U] sunitinib
103.6
9.5
10
*
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
11.3
9.4
17
16
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
+∞
9.4
9
*
L01XE26
ATC
[U] cabozantinib
+∞
9.4
9
*
M907, C61,
ICD-10 Finland
+∞
9.4
9
*
ZXE20
NOMESCO Finland
More than three and less than five hours
2.8
9.2
54
224
D64.9
ICD-10 Finland
Anaemia, unspecified
3.2
9.2
40
140
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
10.6
9.2
17
17
WX200
NOMESCO Finland
Interscalenous plexus blockade
8.4
9.0
19
24
ZXE00
NOMESCO Finland
One hour or less
2.2
9.0
118
706
V03AE01
ATC
polystyrene sulfonate; oral
25.0
9.0
12
5
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
8.8
56
243
L01XE11
ATC
[U] pazopanib
51.8
8.7
10
*
AA1BD
NOMESCO Finland
Extensive CT of head and brain
8.7
8.7
18
22
WX320
NOMESCO Finland
Spinalanesthesy
2.3
8.7
84
441
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
4.0
8.7
26
71
SPAT1255
SPAT
Intravenous administration of medicine
3.8
8.7
27
76
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.5
8.6
67
319
Z49.1
ICD-10 Finland
Extracorporeal dialysis
17.0
8.6
13
8
L75
ICPC
Fracture: femur
28.6
8.5
11
*
Z94.0
ICD-10 Finland
Kidney transplant status
28.6
8.5
11
*
L01AA03
ATC
melphalan; systemic
28.6
8.5
11
*
ZXA00
NOMESCO Finland
Right side
2.3
8.5
88
475
E83.50
ICD-10 Finland
Hypercalcemia
13.4
8.5
14
11
S72.4
ICD-10 Finland
Fracture of lower end of femur
92.9
8.5
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
8.4
83
439
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
8.4
8
*
L01XX50
ATC
[U] ixazomib
+∞
8.4
8
*
M90.0*A18.0
ICD-10 Finland
Bentuberculosis
+∞
8.4
8
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
15.1
8.3
13
9
A41.9
ICD-10 Finland
Sepsis, unspecified
5.0
8.2
18
38
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
8.6
8.2
17
21
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
3.6
8.2
28
84
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.2
8.2
34
116
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.4
8.2
21
51
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
34.5
8.1
10
*
L02BX03
ATC
abiraterone; oral
34.5
8.1
10
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
7.6
8.1
18
25
S42.2
ICD-10 Finland
Fracture of upper end of humerus
4.5
8.1
20
47
352
Kela drug reimbursment
Abiraterone and enzalutamide
22.9
8.1
11
5
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.8
8.1
25
70
N18.8
ICD-10 Finland
Other chronic renal failure
8.2
8.0
17
22
HA1AA
NOMESCO Finland
X-ray mammography
3.2
8.0
33
112
N02AA01
ATC
morphine; systemic, rectal
13.6
8.0
13
10
D70.89
ICD-10 Finland
Neutropenic splenomegaly
13.6
8.0
13
10
NK6AN
NOMESCO Finland
Total body bone isotope imaging
7.4
7.9
18
26
S72.0
ICD-10 Finland
Fracture of neck of femur
4.4
7.9
20
48
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
6.3
7.9
20
34
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
15.6
7.8
12
8
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
46.4
7.8
9
*
1XX32, ,
NOMESCO Finland
46.4
7.8
9
*
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
46.4
7.8
9
*
JN3AD
NOMESCO Finland
Abdominal CT examination
2.9
7.7
38
143
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
19.1
7.7
11
6
127
Kela drug reimbursment
Transplant complication
12.4
7.7
13
11
L04AA06
ATC
mycophenolic acid; systemic
10.5
7.6
14
14
L01EF01
ATC
palbociclib; oral
25.9
7.6
10
*
X76
ICPC
Malignant neoplasm breast female
6.8
7.6
18
28
C10AA07
ATC
rosuvastatin; oral
0.3
7.5
24
640
158
Kela drug reimbursment
Everolimus
82.3
7.5
8
*
L01EX07
ATC
cabozantinib; oral
82.3
7.5
8
*
NFJ62
NOMESCO Finland
Internal fixation of fracture of other parts of femur with plate
82.3
7.5
8
*
A12AA04
ATC
calcium carbonate; oral
9.8
7.4
14
15
SPAT1229
SPAT
Assessment of need for aid
3.4
7.4
27
85
168
Kela drug reimbursment
Axitinib
+∞
7.3
7
*
343
Kela drug reimbursment
Pazopanib
+∞
7.3
7
*
M80.8
ICD-10 Finland
Other osteoporosis with pathological fracture
+∞
7.3
7
*
NGB30
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part - connected prosthesis
+∞
7.3
7
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.2
7.2
30
102
R4190
NOMESCO Finland
Nutritional therapy
5.9
7.2
19
34
L01AA01
ATC
cyclophosphamide; systemic
30.9
7.2
9
*
L04AD02
ATC
tacrolimus; systemic
30.9
7.2
9
*
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
3.5
7.2
26
81
NFU20
NOMESCO Finland
Removal of internal fixation device from femur
20.7
7.2
10
5
N02BE01
ATC
paracetamol; systemic, rectal
3.4
7.1
241
2035
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
10.5
7.1
13
13
116
Kela drug reimbursment
Prostate cancer
3.8
7.0
22
62
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
14.3
7.0
11
8
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
14.3
7.0
11
8
AA3AI
NOMESCO Finland
Cone beam CT of facial bones
14.3
7.0
11
8
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
3.4
6.9
26
83
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
3.9
6.9
21
58
NBJ62
NOMESCO Finland
Internal fixation of fracture of shoulder or upper arm using plate and screws, humerus
9.7
6.9
13
14
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
6.8
111
703
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
6.8
113
721
OAB38
NOMESCO Finland
Psychosocial guidance and counselling
41.2
6.8
8
*
H3603, E103,
ICD-10 Finland
41.2
6.8
8
*
J05AB01
ATC
aciclovir; systemic
2.2
6.8
71
382
WW409
NOMESCO Finland
Other aferesis
23.2
6.7
9
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.8
6.7
35
136
SPAT1254
SPAT
Administration of medicine
2.5
6.6
45
200
N02AX02
ATC
tramadol; systemic, rectal
2.0
6.5
124
827
322
Kela drug reimbursment
Sunitinib
71.5
6.5
7
*
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
71.5
6.5
7
*
NG4AA
NOMESCO Finland
Lower leg X-ray examination
5.4
6.5
18
35
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.9
6.4
32
121
WX002
NOMESCO Finland
Sedation and analgesia
2.2
6.4
63
329
Y88.3
ICD-10 Finland
Sequelae of surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
6.2
6.4
16
27
NFJ54
NOMESCO Finland
Internal fixation of fracture of upper femur with intramedullary nail
11.4
6.4
11
10
ZXA05
NOMESCO Finland
Left side
2.1
6.3
79
453
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
18.6
6.3
9
5
ZX108
NOMESCO Finland
Inhalation
18.6
6.3
9
5
J01FF01
ATC
clindamycin; systemic
2.1
6.3
80
462
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
5.6
6.3
17
32
M907, C5041,
ICD-10 Finland
+∞
6.3
6
*
M907, C795,
ICD-10 Finland
+∞
6.3
6
*
M907, C5099,
ICD-10 Finland
+∞
6.3
6
*
5BA08, ,
NOMESCO Finland
27.4
6.3
8
*
V03AE02
ATC
sevelamer; oral
27.4
6.3
8
*
N25.0
ICD-10 Finland
Renal osteodystrophy
27.4
6.3
8
*
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
6.6
6.3
15
24
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.4
6.2
48
226
ZXD35
NOMESCO Finland
Usual procedure
4.3
6.2
16
39
A10AB05
ATC
insulin aspart; parenteral
2.8
6.2
32
124
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
12.9
6.1
10
8
8312/3-C64.9
ICD-O-3
Renal cell carcinoma, NOS, of kidney, NOS
12.9
6.1
10
8
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
12.9
6.1
10
8
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
7.0
6.1
14
21
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
7.0
6.1
14
21
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
2.6
6.1
39
168
WX202
NOMESCO Finland
Supraclavicular plexus blockade
10.4
6.1
11
11
L01CA04
ATC
vinorelbine; systemic
10.4
6.1
11
11
EBA15
NOMESCO Finland
Extraction of multiple teeth
4.1
6.1
17
44
Z3226
NOMESCO Finland
Physiotherapist
2.2
6.1
58
299
A10AC01
ATC
insulin (human); parenteral
2.7
6.1
33
131
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
63
17.55
85.14
18.8
5.4
54.62
140.27
mg/l
0.40
66
51
79
63
17.55
85.14
18.8
5.4
40.94
28.88
mg/l
0.41
66
51
78
62
17.52
84.17
18.6
5.3
6.78
3.25
ratio
—
5
7
46
41
13.41
45.26
7.0
7.0
551.00
179.14
iu/ml
—
9
7
51
74
8.32
34.86
15.0
2.9
1.57
0.58
g/l
1.22
46
66
110
333
4.98
34.81
2.8
1.9
—
—
—
0
0
54
87
7.57
33.62
15.4
2.3
—
—
—
0
0
164
703
4.59
32.31
16.3
3.0
2.34
2.35
mmol/l
0.72
156
613
89
244
5.02
31.43
2.4
1.8
—
—
—
0
0
89
247
4.95
30.92
2.5
1.8
—
—
—
0
0
203
1060
5.12
29.72
28.6
6.5
1.21
1.22
mmol/l
1.13
171
904
62
144
5.34
26.27
2.3
1.4
—
—
—
0
0
209
1193
4.77
25.18
40.5
9.6
3.90
4.12
e9/l
0.61
189
1048
106
386
3.94
24.92
9.2
2.8
2.51
2.46
mmol/l
2.05
101
340
146
659
3.76
24.84
5.1
3.2
67.37
153.80
e6/l
0.36
119
497
186
996
4.02
24.13
14.4
5.9
22.58
27.69
%
7.42
179
939
30
36
9.29
23.61
1.9
1.6
98.06
97.17
u/ml
—
7
6
37
58
7.27
23.31
2.2
1.8
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
38
62
7.00
23.08
3.3
9.4
0.28
0.37
u/ml
0.73
20
32
37
59
7.14
22.94
2.1
1.8
—
—
—
0
0
183
990
3.84
22.90
13.7
5.7
60.07
57.21
%
2.13
176
933
33
47
7.89
22.60
1.8
1.8
—
—
—
0
0
36
59
6.92
21.73
1.6
1.3
—
—
—
0
0
86
298
3.81
21.30
4.5
2.3
21.32
23.46
%
0.73
73
255
116
490
3.46
21.14
4.9
2.4
—
—
—
0
0
26
30
9.51
21.02
1.3
1.7
—
—
—
0
0
133
613
3.39
20.99
5.2
3.0
0.35
0.44
e6/l
0.30
108
451
63
179
4.32
20.53
9.1
3.7
1.55
2.11
mmol/l
0.44
53
148
60
165
4.42
20.39
8.5
3.7
147.78
71.59
ng/l
1.86
50
144
29
42
7.64
19.51
10.2
2.8
82.14
31.71
u/ml
0.55
29
42
107
448
3.35
19.50
3.6
2.5
4.32
4.94
e6/l
0.21
100
400
171
967
3.23
18.25
5.6
2.5
—
—
—
0
0
148
773
3.11
18.13
5.5
3.0
—
—
—
0
0
69
231
3.70
17.67
6.0
6.9
1.09
1.21
mmol/l
0.09
55
190
68
228
3.68
17.35
6.0
6.9
5.14
5.11
kpa
0.11
63
216
89
357
3.27
17.08
4.6
2.8
1.63
2.07
e6/l
0.29
59
194
27
42
7.05
17.00
1.6
1.3
—
—
—
0
0
27
42
7.05
17.00
1.6
1.3
—
—
—
0
0
25
36
7.57
16.85
1.5
1.6
—
—
—
0
0
118
570
2.95
16.19
8.9
2.7
4510.58
10551.85
umol/l
0.64
111
480
25
38
7.17
16.05
1.8
1.3
—
—
—
0
0
65
224
3.53
15.79
5.4
3.2
—
—
—
0
0
168
1000
2.91
15.27
11.4
12.5
1.18
1.27
inr
0.76
49
287
89
378
3.06
15.26
4.6
2.6
1.17
1.13
e6/l
0.04
59
212
67
245
3.33
14.75
5.6
2.8
13.74
8.10
umol/l
0.36
53
213
24
42
6.19
13.46
2.7
1.9
—
—
—
0
0
24
42
6.19
13.46
2.7
1.9
—
—
—
0
0
22
36
6.58
13.15
2.0
1.5
—
—
—
0
0
21
15
15.10
13.00
1.2
1.3
—
—
—
0
0
21
34
6.63
12.67
2.0
1.4
383.77
277.17
u/ml
0.29
13
18
26
53
5.34
12.44
2.2
1.4
—
—
—
0
0
22
22
10.81
11.75
3.4
3.1
—
—
—
0
0
14
5
29.44
10.84
1.7
1.2
—
—
—
0
0
20
38
5.62
10.28
4.4
3.7
60.45
59.11
%
0.19
20
38
59
251
2.75
9.64
6.0
4.2
6.22
25.96
ug/l
0.62
51
211
19
37
5.46
9.51
4.3
3.1
3.92
4.63
e9/l
0.68
19
37
20
41
5.20
9.48
3.5
2.6
13.93
16.05
%
1.31
12
19
190
1375
2.40
9.13
6.2
4.2
2577.38
155.81
e6/l
—
8
26
12
7
17.87
8.15
1.3
1.7
—
—
—
0
0
130
835
2.11
8.03
3.5
2.2
74.22
77.11
nmol/l
0.54
121
734
16
19
8.89
7.93
1.1
1.2
—
—
—
0
0
20
48
4.43
7.89
2.0
1.2
—
—
—
0
0
82
447
2.22
7.65
3.0
2.1
2.03
1.23
mg/l
0.56
73
360
33
116
3.11
7.54
1.5
1.3
—
—
—
0
0
35
128
3.00
7.47
2.2
1.7
—
—
—
0
0
86
488
2.14
7.20
1.7
1.5
15.47
21.65
nmol/l
5.11
76
407
14
16
9.17
7.14
1.2
1.4
—
—
—
0
0
20
52
4.08
7.12
1.6
1.8
—
—
—
0
0
16
23
7.34
7.11
2.7
2.1
—
—
—
0
0
16
24
7.03
6.93
2.8
2.0
—
—
—
0
0
129
859
1.99
6.90
4.6
2.6
259.13
131.77
ug/l
4.44
122
785
114
729
2.00
6.83
6.7
3.0
35.78
30.69
u/l
0.72
108
694
34
129
2.88
6.80
7.7
6.0
2.21
2.12
mmol/l
0.04
27
101
17
29
6.19
6.73
2.0
1.8
—
—
—
0
0
17
29
6.19
6.73
2.0
1.8
—
—
—
0
0
75
415
2.13
6.63
5.7
3.8
211.81
168.13
ng/l
0.17
62
336
104
659
1.96
6.28
5.7
2.3
53.38
64.23
u/l
0.77
97
603
84
498
2.01
6.11
2.3
1.9
3.42
3.19
mg/l
0.25
69
424
13
18
7.54
6.00
1.5
1.4
—
—
—
0
0
14
22
6.66
5.94
1.4
1.7
—
—
—
0
0
45
212
2.36
5.81
5.1
2.3
36.30
36.04
u/l
0.01
37
181
21
66
3.37
5.73
2.0
2.7
—
—
—
0
0
14
24
6.10
5.61
3.1
2.5
—
—
—
0
0
14
25
5.85
5.45
3.0
2.3
33.64
32.64
pg
0.61
14
25
8
5
16.43
5.44
1.1
1.0
—
—
—
0
0
186
2161
0.52
5.20
4.8
5.3
2.73
2.76
mmol/l
0.20
166
1993
11
15
7.60
5.19
2.5
3.6
—
—
—
0
0
15
40
3.92
5.17
1.6
1.6
—
—
—
0
0
12
19
6.56
5.14
1.4
1.2
—
—
—
0
0
17
50
3.57
5.12
1.4
1.3
—
—
—
0
0
11
16
7.12
5.00
1.1
1.0
—
—
—
0
0
22
79
2.95
4.85
4.5
4.8
1.63
1.61
%
0.04
22
69
183
2126
0.53
4.81
4.5
4.7
4.59
4.69
mmol/l
0.59
163
1969
182
2112
0.54
4.61
4.4
4.7
1.34
1.48
mmol/l
4.58
162
1944
9
11
8.43
4.60
1.3
1.5
—
—
—
0
0
14
32
4.56
4.51
1.6
1.5
1.59
1.58
mmol/l
0.00
14
32
173
2033
0.56
4.50
7.0
6.0
41.49
40.19
mmol/mol
0.79
162
1883
13
28
4.83
4.43
1.2
1.2
—
—
—
0
0
14
33
4.42
4.39
1.6
1.6
—
—
—
0
0
9
12
7.72
4.39
3.8
2.2
—
—
—
0
0
9
12
7.72
4.39
3.3
2.2
—
—
—
0
0
9
12
7.72
4.39
1.3
1.5
—
—
—
0
0
9
12
7.72
4.39
3.3
2.2
—
—
—
0
0
13
29
4.66
4.31
1.7
1.7
—
—
—
0
0
9
13
7.13
4.20
3.4
2.1
—
—
—
0
0
9
13
7.13
4.20
3.4
2.1
—
—
—
0
0
11
22
5.17
4.05
6.0
2.3
92.64
78.17
u/ml
0.07
11
22
7
7
10.23
4.03
1.0
1.0
—
—
—
0
0
9
14
6.61
4.02
1.3
1.6
—
—
—
0
0
117
857
1.66
3.90
2.4
2.0
91.78
96.78
pmol/l
0.48
73
419
7
8
8.95
3.79
2.1
1.4
—
—
—
0
0
93
648
1.68
3.72
4.9
3.4
1420.87
905.63
ng/l
0.98
82
553
8
13
6.31
3.52
2.5
1.5
—
—
—
0
0
8
13
6.31
3.52
2.5
1.5
—
—
—
0
0
6
6
10.19
3.51
2.0
1.3
—
—
—
0
0
179
2045
0.60
3.37
4.4
4.2
1.44
1.29
mmol/l
2.07
160
1872
12
33
3.76
3.34
1.2
1.7
—
—
—
0
0
31
160
2.06
3.21
1.9
2.3
6.50
13.90
nmol/l
4.69
26
148
110
828
1.57
3.10
5.6
3.6
27.05
34.88
ng/l
0.60
94
595
131
1027
1.55
3.07
4.4
3.5
0.00
0.00
estimate
0.50
41
212
8
16
5.12
3.07
2.0
2.4
—
—
—
0
0
9
21
4.40
3.02
3.4
2.0
—
—
—
0
0
9
21
4.40
3.02
3.4
2.0
—
—
—
0
0
9
21
4.40
3.02
3.4
2.0
—
—
—
0
0
131
1034
1.54
2.94
6.5
4.9
0.00
0.00
estimate
-0.00
39
196
186
1587
1.60
2.94
5.2
4.1
28.17
12.25
mm/h
10.63
173
1439
9
22
4.20
2.91
1.3
1.6
24.87
15.14
ug/l
—
9
22
22
103
2.24
2.90
2.1
3.1
594.13
1416.01
u/ml
0.27
16
91
132
1047
1.53
2.88
4.4
3.5
0.00
0.00
estimate
-0.00
38
184
61
406
1.66
2.82
2.3
1.7
1180.23
1195.76
nmol/l
0.04
48
301
13
48
2.80
2.76
2.0
1.5
—
—
—
0
0
5
6
8.46
2.76
1.2
1.2
—
—
—
0
0
9
24
3.84
2.70
2.6
4.3
—
—
—
0
0
17
74
2.39
2.64
3.8
1.9
—
—
—
0
0
189
2101
0.64
2.60
5.1
4.7
6.01
6.01
mmol/l
0.00
170
1925
6
11
5.55
2.55
3.0
1.5
—
—
—
0
0
6
11
5.55
2.55
3.0
1.5
—
—
—
0
0
12
267
0.42
2.32
4.3
4.6
35.00
32.33
%
—
6
180
6
15
4.07
2.05
1.2
2.0
—
—
—
0
0
6
15
4.07
2.05
1.2
2.0
—
—
—
0
0
14
63
2.29
2.05
2.6
1.8
—
—
—
0
0
46
312
1.58
1.96
1.3
1.4
—
—
—
0
0
5
11
4.61
1.95
1.6
2.5
—
—
—
0
0
5
11
4.61
1.95
2.2
1.4
—
—
—
0
0
8
29
2.81
1.80
1.0
1.1
—
—
—
0
0
11
47
2.40
1.80
1.2
1.6
313.00
227.80
miu/ml
—
5
23
13
61
2.19
1.74
1.7
1.3
132.57
280.31
ug/g
—
8
33
8
30
2.72
1.74
2.5
1.6
—
—
—
0
0
8
30
2.72
1.74
2.5
1.6
—
—
—
0
0
8
30
2.72
1.74
2.5
1.6
—
—
—
0
0
8
30
2.72
1.74
2.5
1.6
—
—
—
0
0
8
30
2.72
1.74
2.5
1.6
—
—
—
0
0
5
13
3.90
1.72
1.4
1.2
—
—
—
0
0
13
62
2.15
1.68
1.1
1.3
—
—
—
0
0
8
31
2.63
1.67
2.5
1.5
—
—
—
0
0
11
51
2.21
1.53
1.2
1.3
—
—
—
0
0
5
17
2.98
1.36
1.4
1.8
—
—
—
0
0
69
545
1.36
1.35
4.4
3.6
0.00
0.00
estimate
-0.00
36
187
11
56
2.01
1.24
1.2
1.7
—
0.09
—
0
11
28
190
1.53
1.22
2.2
2.2
4.46
7.86
ug/l
1.15
19
172
11
57
1.97
1.19
1.1
1.1
—
—
—
0
0
12
65
1.89
1.15
1.5
1.1
—
—
—
0
0
12
65
1.89
1.15
1.5
1.1
—
—
—
0
0
10
178
0.54
1.08
1.8
1.8
—
—
—
0
0
16
248
0.62
1.04
23.3
6.9
—
—
—
0
0
20
290
0.66
0.97
1.4
1.4
—
—
—
0
0
9
51
1.79
0.95
1.1
1.3
—
—
—
0
0
223
2122
1.35
0.93
58.4
13.4
26.20
23.40
mg/l
0.81
216
1669
16
102
1.61
0.93
4.3
2.4
0.68
0.66
%
0.11
16
102
24
169
1.46
0.91
4.4
3.0
48.75
61.77
ml/min/173m2
—
8
75
91
789
1.24
0.86
4.8
3.6
—
—
—
0
0
16
105
1.56
0.84
4.3
2.4
0.86
1.28
%
1.75
16
105
18
122
1.51
0.82
1.1
1.2
207.38
135.73
iu/ml
—
8
50
0
24
0.00
0.79
0.0
1.2
—
—
—
0
0
0
24
0.00
0.79
0.0
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
50
600
0.79
0.74
4.6
4.4
31.61
22.04
%
0.87
26
281
130
1187
1.19
0.69
3.2
2.8
—
—
—
0
0
5
27
1.87
0.69
1.6
1.4
—
—
—
0
0
227
2341
0.77
0.68
75.4
20.4
3.99
4.50
e12/l
29.40
221
2268
227
2340
0.77
0.67
75.7
20.4
36.48
40.22
%
22.80
215
2188
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
14
97
1.47
0.60
1.7
2.6
40.56
40.03
u/l
0.03
14
89
9
134
0.66
0.53
2.3
1.8
—
—
—
0
0
187
1952
0.85
0.52
7.1
4.6
2.09
2.55
mu/l
0.33
174
1762
29
353
0.80
0.50
1.2
1.2
1.27
12.52
u/ml
—
7
119
7
106
0.65
0.50
1.0
1.0
—
—
—
0
0
14
102
1.39
0.48
1.6
1.2
—
—
—
0
0
211
2039
1.18
0.46
52.5
12.9
73.95
79.21
ml/min/173m2
2.07
190
1672
5
32
1.57
0.42
4.2
2.7
107.20
105.97
mmol/l
—
5
32
5
34
1.48
0.40
1.0
1.1
—
—
—
0
0
38
433
0.86
0.35
2.9
3.1
1.15
0.83
ug/l
0.71
28
289
9
117
0.76
0.28
1.9
1.7
—
—
—
0
0
226
2217
1.14
0.27
57.6
15.8
4.01
3.98
mmol/l
0.78
221
2153
20
233
0.85
0.25
2.0
2.0
1.71
1.49
%
0.51
14
200
76
712
1.10
0.24
4.8
3.8
53.99
8.11
mg/mmol
1.50
52
430
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
53
1.14
0.19
1.0
1.1
—
3.59
—
0
7
138
1413
0.95
0.13
4.1
3.1
66.35
49.47
u/l
1.42
127
1304
223
2253
0.93
0.12
63.5
16.3
97.68
78.06
umol/l
3.64
223
2253
6
56
1.07
0.08
1.8
1.8
—
—
—
0
0
77
748
1.04
0.08
6.5
4.9
5.42
2.62
ug/l
0.84
67
674
35
366
0.95
0.07
1.2
1.2
42.17
37.18
iu/ml
—
6
120
44
450
0.97
0.03
1.4
1.2
1.47
1.15
u/ml
—
7
114
161
1599
1.02
0.02
6.9
3.8
14.76
14.75
pmol/l
0.01
153
1430
0
5
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
20.32
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
-0.00
1.0
1.2
—
30.68
—
0
8
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
7.06
—
0
5
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
9.67
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_OSTEOPATHYINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOPATHYINOTH | 9.092 [6.48, 12.75] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.114 |
During the follow-up period (1.1.1998 — 31.12.2019), 430 out of 733 females with M13_OSTEOPATHYINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOPATHYINOTH | 7.116 [4.53, 11.17] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 356 out of 636 males with M13_OSTEOPATHYINOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_OSTEOPATHYINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.763% | 1.031% |
| 5 | 4.847% | 6.694% |
| 10 | 12.775% | 16.411% |
| 15 | 22.181% | 29.36% |
| 20 | 35.371% | 45.528% |
Relationships between endpoints
↥Index endpoint: M13_OSTEOPATHYINOTH – Osteopathy in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data